| 05/04/2026 5:00 PM | EVNIN LUKE (1134657) Reporting Werewolf Therapeutics (1785530) Issuer | Form 4 Statement of changes in beneficial ownership of securities | |
| 05/01/2026 3:52 PM | UBS Oncology Impact Fund L.P. (1691428) Reporting Werewolf Therapeutics (1785530) Subject | Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
| 05/01/2026 3:52 PM | MPM Asset Management Investors BV2014 LLC (1609495) Reporting Werewolf Therapeutics (1785530) Subject | Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
| 05/01/2026 3:51 PM | MPM ASSET MANAGEMENT LLC (1263048) Reporting Werewolf Therapeutics (1785530) Subject | Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
| 05/01/2026 3:51 PM | MPM ONCOLOGY INNOVATIONS FUND LP (1719960) Reporting Werewolf Therapeutics (1785530) Subject | Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
| 05/01/2026 3:51 PM | MPM BioVentures 2014, L.P. (1609492) Reporting Werewolf Therapeutics (1785530) Subject | Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
| 05/01/2026 3:52 PM | MPM BioVentures 2014 (0) B Werewolf Therapeutics (1785530) Subject | Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
| 04/29/2026 6:16 PM | EVNIN LUKE (1134657) Reporting Werewolf Therapeutics (1785530) Issuer | Form 4 Statement of changes in beneficial ownership of securities | |
| 04/29/2026 3:47 PM | MPM ONCOLOGY INNOVATIONS FUND LP (1719960) Reporting Werewolf Therapeutics (1785530) Subject | Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
| 04/29/2026 3:47 PM | MPM BioVentures 2014, L.P. (1609492) Reporting Werewolf Therapeutics (1785530) Subject | Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
| 04/29/2026 3:47 PM | MPM BioVentures 2014 (0) B Werewolf Therapeutics (1785530) Subject | Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
Get the Latest News and Ratings for HOWL and Related Stocks Enter your email address below to receive the latest news and analysts' ratings for Werewolf Therapeutics and its competitors with MarketBeat's FREE daily newsletter.
|
| 04/29/2026 3:48 PM | UBS Oncology Impact Fund L.P. (1691428) Reporting Werewolf Therapeutics (1785530) Subject | Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
| 04/29/2026 3:48 PM | MPM Asset Management Investors BV2014 LLC (1609495) Reporting Werewolf Therapeutics (1785530) Subject | Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
| 04/29/2026 3:48 PM | MPM ASSET MANAGEMENT LLC (1263048) Reporting Werewolf Therapeutics (1785530) Subject | Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
| 04/27/2026 3:59 PM | MPM ONCOLOGY INNOVATIONS FUND LP (1719960) Reporting Werewolf Therapeutics (1785530) Subject | Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
| 04/27/2026 4:00 PM | MPM BioVentures 2014, L.P. (1609492) Reporting Werewolf Therapeutics (1785530) Subject | Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
| 04/27/2026 4:00 PM | UBS Oncology Impact Fund L.P. (1691428) Reporting Werewolf Therapeutics (1785530) Subject | Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
| 04/27/2026 4:00 PM | MPM BioVentures 2014 (0) B Werewolf Therapeutics (1785530) Subject | Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
| 04/27/2026 4:01 PM | MPM Asset Management Investors BV2014 LLC (1609495) Reporting Werewolf Therapeutics (1785530) Subject | Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
| 04/27/2026 4:01 PM | MPM ASSET MANAGEMENT LLC (1263048) Reporting Werewolf Therapeutics (1785530) Subject | Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
| 03/27/2026 6:07 AM | Werewolf Therapeutics (1785530) Filer | Form 8-K Current report pursuant to Section 13 or 15(d) | |
| 03/27/2026 6:12 AM | Werewolf Therapeutics (1785530) Filer | Form 10-K Annual report pursuant to Section 13 or 15(d) | |
| 02/24/2026 4:26 PM | Werewolf Therapeutics (1785530) Filer | Form 8-K Current report pursuant to Section 13 or 15(d) | |
| 02/11/2026 2:46 PM | Longwood Fund III, L.P. (1640546) Filed by Werewolf Therapeutics (1785530) Subject | Form SCHEDULE 13G/A | |
| 02/06/2026 3:41 PM | Werewolf Therapeutics (1785530) Filer | Form 8-K Current report pursuant to Section 13 or 15(d) | |
| 01/20/2026 3:07 PM | EVNIN LUKE (1134657) Reporting Werewolf Therapeutics (1785530) Issuer | Form 4 Statement of changes in beneficial ownership of securities | |
| 01/16/2026 4:36 PM | MPM BioVentures 2014, L.P. (1609492) Filed by Werewolf Therapeutics (1785530) Subject | Form SCHEDULE 13D/A | |
| 01/15/2026 4:22 PM | EVNIN LUKE (1134657) Reporting Werewolf Therapeutics (1785530) Issuer | Form 4 Statement of changes in beneficial ownership of securities | |
| 01/12/2026 4:09 PM | EVNIN LUKE (1134657) Reporting Werewolf Therapeutics (1785530) Issuer | Form 4 Statement of changes in beneficial ownership of securities | |
| 01/07/2026 4:12 PM | EVNIN LUKE (1134657) Reporting Werewolf Therapeutics (1785530) Issuer | Form 4 Statement of changes in beneficial ownership of securities | |
| 01/06/2026 3:58 PM | MPM Asset Management Investors BV2014 LLC (1609495) Reporting Werewolf Therapeutics (1785530) Subject | Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
| 01/06/2026 3:59 PM | MPM ASSET MANAGEMENT LLC (1263048) Reporting Werewolf Therapeutics (1785530) Subject | Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
| 01/06/2026 3:54 PM | MPM ONCOLOGY INNOVATIONS FUND LP (1719960) Reporting Werewolf Therapeutics (1785530) Subject | Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
| 01/06/2026 3:54 PM | MPM BioVentures 2014, L.P. (1609492) Reporting Werewolf Therapeutics (1785530) Subject | Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
| 01/06/2026 3:56 PM | UBS Oncology Impact Fund L.P. (1691428) Reporting Werewolf Therapeutics (1785530) Subject | Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
| 01/06/2026 3:57 PM | MPM BioVentures 2014 (0) B Werewolf Therapeutics (1785530) Subject | Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
| 01/02/2026 4:32 PM | EVNIN LUKE (1134657) Reporting Werewolf Therapeutics (1785530) Issuer | Form 4 Statement of changes in beneficial ownership of securities | |
| 12/29/2025 5:59 PM | MPM BioVentures 2014, L.P. (1609492) Filed by Werewolf Therapeutics (1785530) Subject | Form SCHEDULE 13D/A | |
| 12/29/2025 4:27 PM | EVNIN LUKE (1134657) Reporting Werewolf Therapeutics (1785530) Issuer | Form 4 Statement of changes in beneficial ownership of securities | |
| 12/29/2025 3:45 PM | MPM ASSET MANAGEMENT LLC (1263048) Reporting Werewolf Therapeutics (1785530) Subject | Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
| 12/29/2025 3:45 PM | MPM BioVentures 2014 (0) B Werewolf Therapeutics (1785530) Subject | Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
|
| 12/29/2025 3:46 PM | MPM BioVentures 2014, L.P. (1609492) Reporting Werewolf Therapeutics (1785530) Subject | Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
| 12/29/2025 3:47 PM | MPM ONCOLOGY INNOVATIONS FUND LP (1719960) Reporting Werewolf Therapeutics (1785530) Subject | Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
| 12/29/2025 3:47 PM | UBS Oncology Impact Fund L.P. (1691428) Reporting Werewolf Therapeutics (1785530) Subject | Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
| 12/29/2025 3:48 PM | MPM Asset Management Investors BV2014 LLC (1609495) Reporting Werewolf Therapeutics (1785530) Subject | Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
| 12/22/2025 3:55 PM | MPM ASSET MANAGEMENT LLC (1263048) Reporting Werewolf Therapeutics (1785530) Subject | Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
| 12/22/2025 3:56 PM | MPM BioVentures 2014 (0) B Werewolf Therapeutics (1785530) Subject | Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
| 12/22/2025 3:56 PM | MPM ONCOLOGY INNOVATIONS FUND LP (1719960) Reporting Werewolf Therapeutics (1785530) Subject | Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
| 12/22/2025 3:56 PM | UBS Oncology Impact Fund L.P. (1691428) Reporting Werewolf Therapeutics (1785530) Subject | Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
| 12/22/2025 3:57 PM | MPM Asset Management Investors BV2014 LLC (1609495) Reporting Werewolf Therapeutics (1785530) Subject | Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
| 12/22/2025 3:57 PM | MPM BioVentures 2014, L.P. (1609492) Reporting Werewolf Therapeutics (1785530) Subject | Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
| 12/18/2025 7:24 AM | Werewolf Therapeutics (1785530) Filer | Form 8-K Current report pursuant to Section 13 or 15(d) | |
| 12/17/2025 5:28 PM | Werewolf Therapeutics (1785530) Issuer | Form 4 Statement of changes in beneficial ownership of securities | |
| 12/17/2025 5:28 PM | EVNIN LUKE (1134657) Reporting EVNIN LUKE (1134657) Reporting Werewolf Therapeutics (1785530) Issuer | Form 4 Statement of changes in beneficial ownership of securities | |
| 12/12/2025 4:32 PM | EVNIN LUKE (1134657) Reporting Werewolf Therapeutics (1785530) Issuer | Form 4 Statement of changes in beneficial ownership of securities | |
| 12/10/2025 4:01 PM | MPM BioVentures 2014 (0) B Werewolf Therapeutics (1785530) Subject | Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
| 12/10/2025 4:02 PM | MPM BioVentures 2014, L.P. (1609492) Reporting Werewolf Therapeutics (1785530) Subject | Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
| 12/10/2025 4:02 PM | MPM Asset Management Investors BV2014 LLC (1609495) Reporting Werewolf Therapeutics (1785530) Subject | Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
| 12/10/2025 4:03 PM | UBS Oncology Impact Fund L.P. (1691428) Reporting Werewolf Therapeutics (1785530) Subject | Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
| 12/10/2025 4:04 PM | MPM ONCOLOGY INNOVATIONS FUND LP (1719960) Reporting Werewolf Therapeutics (1785530) Subject | Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
| 12/10/2025 4:05 PM | MPM ASSET MANAGEMENT LLC (1263048) Reporting Werewolf Therapeutics (1785530) Subject | Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
| 12/09/2025 4:07 PM | EVNIN LUKE (1134657) Reporting Werewolf Therapeutics (1785530) Issuer | Form 4 Statement of changes in beneficial ownership of securities | |
| 12/04/2025 5:18 PM | GADICKE ANSBERT (1134655) Reporting MPM ASSET MANAGEMENT LLC (1263048) Reporting MPM BioImpact LLC (1687078) Reporting MPM Oncology Innovations Fund GP LLC (1857903) Reporting MPM ONCOLOGY INNOVATIONS FUND LP (1719960) Reporting Oncology Impact Fund (0) Cayman UBS Oncology Impact Fund L.P. (1691428) Reporting Werewolf Therapeutics (1785530) Issuer | Form 4 Statement of changes in beneficial ownership of securities | |
| 12/04/2025 5:19 PM | MPM Asset Management Investors BV2014 LLC (1609495) Reporting MPM BioVentures 2014 (0) B MPM BioVentures 2014 GP LLC (1765091) Reporting MPM BioVentures 2014 LLC (1765021) Reporting MPM BioVentures 2014, L.P. (1609492) Reporting Werewolf Therapeutics (1785530) Issuer | Form 4 Statement of changes in beneficial ownership of securities | |
| 12/04/2025 5:20 PM | EVNIN LUKE (1134657) Reporting Werewolf Therapeutics (1785530) Issuer | Form 4 Statement of changes in beneficial ownership of securities | |
| 12/03/2025 6:04 PM | MPM BioVentures 2014, L.P. (1609492) Filed by Werewolf Therapeutics (1785530) Subject | Form SCHEDULE 13D/A | |
| 12/01/2025 5:11 PM | GADICKE ANSBERT (1134655) Reporting MPM ASSET MANAGEMENT LLC (1263048) Reporting MPM BioImpact LLC (1687078) Reporting MPM Oncology Innovations Fund GP LLC (1857903) Reporting MPM ONCOLOGY INNOVATIONS FUND LP (1719960) Reporting Oncology Impact Fund (0) Cayman UBS Oncology Impact Fund L.P. (1691428) Reporting Werewolf Therapeutics (1785530) Issuer | Form 4 Statement of changes in beneficial ownership of securities | |
| 12/01/2025 5:12 PM | MPM Asset Management Investors BV2014 LLC (1609495) Reporting MPM BioVentures 2014 (0) B MPM BioVentures 2014 GP LLC (1765091) Reporting MPM BioVentures 2014 LLC (1765021) Reporting MPM BioVentures 2014, L.P. (1609492) Reporting Werewolf Therapeutics (1785530) Issuer | Form 4 Statement of changes in beneficial ownership of securities | |
| 12/01/2025 5:13 PM | EVNIN LUKE (1134657) Reporting Werewolf Therapeutics (1785530) Issuer | Form 4 Statement of changes in beneficial ownership of securities | |
| 11/25/2025 5:03 PM | GADICKE ANSBERT (1134655) Reporting MPM ASSET MANAGEMENT LLC (1263048) Reporting MPM BioImpact LLC (1687078) Reporting MPM Oncology Innovations Fund GP LLC (1857903) Reporting MPM ONCOLOGY INNOVATIONS FUND LP (1719960) Reporting Oncology Impact Fund (0) Cayman UBS Oncology Impact Fund L.P. (1691428) Reporting Werewolf Therapeutics (1785530) Issuer | Form 4 Statement of changes in beneficial ownership of securities | |
| 11/25/2025 5:04 PM | MPM Asset Management Investors BV2014 LLC (1609495) Reporting MPM BioVentures 2014 (0) B MPM BioVentures 2014 GP LLC (1765091) Reporting MPM BioVentures 2014 LLC (1765021) Reporting MPM BioVentures 2014, L.P. (1609492) Reporting Werewolf Therapeutics (1785530) Issuer | Form 4 Statement of changes in beneficial ownership of securities | |
| 11/25/2025 5:05 PM | EVNIN LUKE (1134657) Reporting Werewolf Therapeutics (1785530) Issuer | Form 4 Statement of changes in beneficial ownership of securities | |
| 11/24/2025 3:31 PM | MPM Asset Management Investors BV2014 LLC (1609495) Reporting Werewolf Therapeutics (1785530) Subject | Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
| 11/24/2025 3:31 PM | MPM BioVentures 2014, L.P. (1609492) Reporting Werewolf Therapeutics (1785530) Subject | Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
| 11/24/2025 3:32 PM | UBS Oncology Impact Fund L.P. (1691428) Reporting Werewolf Therapeutics (1785530) Subject | Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
| 11/24/2025 3:33 PM | MPM ONCOLOGY INNOVATIONS FUND LP (1719960) Reporting Werewolf Therapeutics (1785530) Subject | Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
| 11/24/2025 3:33 PM | MPM ASSET MANAGEMENT LLC (1263048) Reporting Werewolf Therapeutics (1785530) Subject | Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
| 11/24/2025 3:34 PM | MPM BioVentures 2014 (0) B Werewolf Therapeutics (1785530) Subject | Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
| 11/20/2025 4:50 PM | GADICKE ANSBERT (1134655) Reporting MPM ASSET MANAGEMENT LLC (1263048) Reporting MPM BioImpact LLC (1687078) Reporting MPM Oncology Innovations Fund GP LLC (1857903) Reporting MPM ONCOLOGY INNOVATIONS FUND LP (1719960) Reporting Oncology Impact Fund (0) Cayman UBS Oncology Impact Fund L.P. (1691428) Reporting Werewolf Therapeutics (1785530) Issuer | Form 4 Statement of changes in beneficial ownership of securities | |
| 11/20/2025 4:51 PM | MPM Asset Management Investors BV2014 LLC (1609495) Reporting MPM BioVentures 2014 (0) B MPM BioVentures 2014 GP LLC (1765091) Reporting MPM BioVentures 2014 LLC (1765021) Reporting MPM BioVentures 2014, L.P. (1609492) Reporting Werewolf Therapeutics (1785530) Issuer | Form 4 Statement of changes in beneficial ownership of securities | |
| 11/20/2025 4:52 PM | EVNIN LUKE (1134657) Reporting Werewolf Therapeutics (1785530) Issuer | Form 4 Statement of changes in beneficial ownership of securities | |
| 11/17/2025 7:00 PM | MPM BioVentures 2014, L.P. (1609492) Filed by Werewolf Therapeutics (1785530) Subject | Form SCHEDULE 13D/A | |
| 11/17/2025 6:20 PM | GADICKE ANSBERT (1134655) Reporting MPM ASSET MANAGEMENT LLC (1263048) Reporting MPM BioImpact LLC (1687078) Reporting MPM Oncology Innovations Fund GP LLC (1857903) Reporting MPM ONCOLOGY INNOVATIONS FUND LP (1719960) Reporting Oncology Impact Fund (0) Cayman UBS Oncology Impact Fund L.P. (1691428) Reporting Werewolf Therapeutics (1785530) Issuer | Form 4 Statement of changes in beneficial ownership of securities | |
| 11/17/2025 6:22 PM | MPM Asset Management Investors BV2014 LLC (1609495) Reporting MPM BioVentures 2014 (0) B MPM BioVentures 2014 GP LLC (1765091) Reporting MPM BioVentures 2014 LLC (1765021) Reporting MPM BioVentures 2014, L.P. (1609492) Reporting Werewolf Therapeutics (1785530) Issuer | Form 4 Statement of changes in beneficial ownership of securities | |
| 11/17/2025 6:23 PM | EVNIN LUKE (1134657) Reporting Werewolf Therapeutics (1785530) Issuer | Form 4 Statement of changes in beneficial ownership of securities | |
| 11/17/2025 3:56 PM | UBS Oncology Impact Fund L.P. (1691428) Reporting Werewolf Therapeutics (1785530) Subject | Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
| 11/17/2025 3:57 PM | MPM ONCOLOGY INNOVATIONS FUND LP (1719960) Reporting Werewolf Therapeutics (1785530) Subject | Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
| 11/17/2025 3:58 PM | MPM ASSET MANAGEMENT LLC (1263048) Reporting Werewolf Therapeutics (1785530) Subject | Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
| 11/17/2025 3:59 PM | MPM BioVentures 2014 (0) B Werewolf Therapeutics (1785530) Subject | Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
| 11/17/2025 3:59 PM | MPM Asset Management Investors BV2014 LLC (1609495) Reporting Werewolf Therapeutics (1785530) Subject | Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
| 11/17/2025 3:56 PM | MPM BioVentures 2014, L.P. (1609492) Reporting Werewolf Therapeutics (1785530) Subject | Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
|
| 11/12/2025 6:49 PM | EVNIN LUKE (1134657) Reporting Werewolf Therapeutics (1785530) Issuer | Form 4 Statement of changes in beneficial ownership of securities | |
| 11/12/2025 6:32 PM | MPM Asset Management Investors BV2014 LLC (1609495) Reporting MPM BioVentures 2014 (0) B MPM BioVentures 2014 GP LLC (1765091) Reporting MPM BioVentures 2014 LLC (1765021) Reporting MPM BioVentures 2014, L.P. (1609492) Reporting Werewolf Therapeutics (1785530) Issuer | Form 4 Statement of changes in beneficial ownership of securities | |
| 11/12/2025 6:31 PM | GADICKE ANSBERT (1134655) Reporting MPM ASSET MANAGEMENT LLC (1263048) Reporting MPM BioImpact LLC (1687078) Reporting MPM Oncology Innovations Fund GP LLC (1857903) Reporting MPM ONCOLOGY INNOVATIONS FUND LP (1719960) Reporting Oncology Impact Fund (0) Cayman UBS Oncology Impact Fund L.P. (1691428) Reporting Werewolf Therapeutics (1785530) Issuer | Form 4 Statement of changes in beneficial ownership of securities | |
| 11/10/2025 3:51 PM | MPM Asset Management Investors BV2014 LLC (1609495) Reporting Werewolf Therapeutics (1785530) Subject | Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
| 11/10/2025 3:51 PM | MPM ASSET MANAGEMENT LLC (1263048) Reporting Werewolf Therapeutics (1785530) Subject | Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
| 11/10/2025 3:53 PM | MPM BioVentures 2014, L.P. (1609492) Reporting Werewolf Therapeutics (1785530) Subject | Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
| 11/10/2025 3:53 PM | MPM ONCOLOGY INNOVATIONS FUND LP (1719960) Reporting Werewolf Therapeutics (1785530) Subject | Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
| 11/10/2025 3:54 PM | UBS Oncology Impact Fund L.P. (1691428) Reporting Werewolf Therapeutics (1785530) Subject | Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
| 11/10/2025 3:54 PM | MPM BioVentures 2014 (0) B Werewolf Therapeutics (1785530) Subject | Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |